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Opioid use disorder (OUD) is a major public health issue that has reached epidemic levels 
in some parts of the world. It is a chronic and complex neurobiological disease associated 
with frequent relapse to drug taking. Craving, defined as an overwhelmingly strong 
desire or need to use a drug, is a central component of OUD and other substance use 
disorders. In this review, we describe the neurobiological and neuroendocrine pathways 
that underpin craving in OUD and also focus on the importance of assessing and treating 
craving in clinical practice. Craving is strongly associated with patients returning to opioid 
misuse and is therefore an important treatment target to reduce the risk of relapse and 
improve patients’ quality of life. Opioid agonist therapies (OAT), such as buprenorphine 
and methadone, can significantly reduce craving and relapse risk, and it is essential that 
patients are treated optimally with these therapies. There is also evidence to support 
the benefits of non-pharmacological approaches, such as cognitive behavioral therapy 
and mindfulness-based interventions, as supplementary treatments to opioid agonist 
therapies. However, despite the positive impact of these treatments on craving, many 
OUD patients continue to suffer with negative affect and dysphoria. There is a clear 
need for further studies to progress our understanding of the neurobiological basis of 
craving and addiction and to identify novel therapeutic strategies as well as to optimize 
the use of existing treatments to improve outcomes for the growing numbers of patients 
affected by OUD.
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INTRODUCTION
Opioid use disorder (OUD) is a major public health burden worldwide and is associated with 
substantial mortality and morbidity (1, 2). A key component of OUD is the development of long-
lasting drug craving (3–5), whether in the context of prescribed opioids, such as for analgesic 
purposes, or illicitly acquired heroin. Although a universally agreed definition of drug craving is 
lacking, in the literature, it has been defined as an intrusive and overwhelming strong desire or 
compulsion to use a drug because of the memory of the pleasant rewarding effects superimposed 
on a negative emotional state (6–8). Craving is considered to be central to the motivational drive in 
addiction (9) and is recognized as an integral component of dependence syndromes, as acknowledged 
by its incorporation within the latest Diagnostic and Statistical Manual of Mental Disorders 5 
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classification system for substance use disorders (10). Craving is 
also included within the definition of opioid dependence in the 
recently updated 11th Revision of the International Classification 
of Diseases system (11).
Craving is a common symptom across substance use disorders 
beyond opioids, including those relating to alcohol, nicotine, 
cannabis, cocaine, and other psychoactive substances (11). 
Although there have been several articles in recent years 
reviewing data in drug craving (9, 12), a focused review of 
opioid-specific evidence is lacking. In this review, we will discuss 
the neurobiological foundations for craving, approaches to 
assessing craving, the importance of craving for predicting the 
risk of relapse in clinical practice, and the potential for therapies 
to target craving in OUD.
To identify relevant references, a narrative literature search 
was conducted in April 2019. The PubMed database was searched 
using terms related to opioids and craving. Only articles in 
English were included. Additional references were identified 
through searching the bibliographies of retrieved articles.
NEUROBIOLOGY OF ADDICTION AND 
CRAVING IN OPIOID USE DISORDER
Addiction is a chronic relapsing disease with a neurological basis 
(13, 14). It is therefore important to explore the neurobiological 
underpinnings of craving in order to better understand the disease 
process and to identify potential targets of anti-craving medications 
and non-pharmacological interventions (15). A range of theories 
describing various aspects of neuroadaptation in addiction 
have been proposed, including opponent, inhibitory control, 
reward deficiency, incentive sensitization, aberrant learning, 
and anti-reward theory (16). The opponent theory, for example, 
proposes that the euphoria induced by a drug is opposed by a 
counteracting process that eventually masks the initial hedonic 
effects (17). In addition, the incentive sensitization theory has 
been proposed as being particularly relevant for craving. 
This theory suggests that repeated use of illicit drugs induces 
neuroadaptations leading to enduring sensitization of dopamine 
systems with subsequent hyperreactivity in response to drug cues 
and a pathological degree of incentive salience, manifesting as 
a disproportionate motivation to pursue the drug (16, 18, 19). 
Such an increase in salience associated with drug-related cues is 
coupled with a reduced sensitivity to normal, non-drug-related 
rewards (20). A detailed explanation of the various theories of 
addiction is beyond the scope of the present review and can be 
found elsewhere (16).
Although early models of addiction focused on hedonic 
reward, there is now evidence that negative reinforcement may 
have a particularly important role in maintaining addictive 
behaviors (21). In this review, we focus our discussion on 
the neurobiology of addiction based on the cycle of addiction 
developed by Koob and colleagues (22) (Figure 1).
The cycle of addiction has been proposed to involve 
three key drivers that underlie the neurobiological changes 
associated with opioid dependence: i) drug-liking (due to drug 
intoxication), of which the positive emotions, such as euphoria, 
are positively reinforcing and increase the probability of using 
the drug in the early stage of addiction; ii) withdrawal and 
negative affect, which is associated with negative reinforcement 
because of the desire to consume a drug in order to improve 
the affective state and to offset the withdrawal symptoms; 
and, iii)  craving, which relates to the intrusive preoccupation 
of wanting to use a drug, which can also be associated with 
FIGURE 1 | Drivers in the cycle of addiction. The addiction cycle involves three key drivers: (1) pleasurable drug-liking (associated with euphoria in the early stages 
of addiction), (2) withdrawal and negative affect (the stress and dysphoria associated with withdrawal from a drug), and (3) craving for the drug and ongoing negative 
affect. Underlying these key drivers are neuroadaptations associated with reward deficit, stress surfeit, and executive function disorders, respectively. Figure 
reproduced and adapted under the CC-BY license from the ACH Servier Research Group (22).
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negative affect (23, 24). All psychoactive drugs target the reward 
system in the brain producing the positive feelings and emotions 
that are associated with addiction or dependence (24). This 
system is opposed by the anti-reward system, which is responsible 
for the stress, dysphoria, and craving associated with withdrawal 
(Figure 2) (14). Addiction occurs when there is a deviation from 
the homeostatic set-point created by the reward and anti-reward 
systems in the brain (Figure 3) (25).
FIGURE 3 | Homeostatic set-point in reward and anti-reward. The set-point of hedonic tone is determined by the balance between the opposing reward and 
anti-reward pathways. As addiction develops, there is a change in hedonic tone resulting from the deviation of the set-point that occurs when the reward 
system is down-regulated and the anti-reward system becomes dominant (25). CRF, corticotropin-releasing factor; DA, dopamine; GABA, γ-aminobutyric acid; 
NA, noradrenaline.
FIGURE 2 | Interface between addiction and stress: Reward versus anti-reward. During acute drug use, the reward system becomes overactive and dopamine 
is upregulated, especially in the NAc, giving rise to positive reinforcing symptoms, such as drug-liking and euphoria. In the dependent state, the reward system 
becomes down-regulated and the anti-reward system becomes upregulated and CRF released from the hypothalamic neurons acts on the pituitary to release 
ACTH, which in turn results in the secretion of cortisol by the adrenal glands. The production of CRF is initially controlled by negative feedback of cortisol on the 
hippocampus and hypothalamus. However, this is eventually overcome by the production of extra-hypothalamic CRF from the amygdala in a feed-forward manner, 
which maintains the sympathetic nervous system stress response. This latter pathway produces a stress surfeit that contributes to the negative emotions associated 
with withdrawal and which goes unbuffered because of the hypodopaminergic tone in the mesolimbic pathway. ACTH, adrenocorticotropic hormone; BP, blood 
pressure; CRF, corticotropin-releasing factor; DA, dopamine; MFB, medial forebrain bundle; NA, noradrenaline; NAc, nucleus accumbens; PFC, prefrontal cortex; 
VTA, ventral tegmental area.
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During acute intoxication, the mesolimbic pathway, comprising 
dopaminergic projections from the ventral tegmental area to the 
nucleus accumbens (NAc) and frontal cortex, becomes active 
and dopamine is upregulated, especially in the NAc. This gives 
rise to positive reinforcing symptoms, such as euphoria (hence 
the term reward pathway) (14, 24, 26). Other neurotransmitter 
systems implicated in positive reinforcement include endogenous 
opioids, γ-aminobutyric acid, glutamate, neuropeptide Y, and 
glucocorticoids (14). The frontal cortex function is relatively 
preserved in the early stages of addiction and is important in the 
subjective effects of craving, attribution of salience (assignment of 
relative value), and inhibitory behavioral control (24).
As addiction progresses, the anti-reward system is recruited 
through the extended amygdala [a macrostructure consisting 
of the NAc, amygdala, hypothalamus, and bed nucleus of the 
stria terminalis (27)] and activates stress pathways mediated by 
increases in dynorphins, corticotrophin-releasing factor (CRF), 
and noradrenaline (27). Dynorphins are opioid peptides that 
are widely distributed in the central nervous system and are 
increasingly recognized as key mediators of negative emotional 
states (27). In addiction, dynorphins are believed to play an 
important role in dysphoria, anhedonia, and compulsive drug-
seeking behavior (27, 28). In response to acute intoxication, excess 
activation of dopamine receptors in the NAc can upregulate the 
production of dynorphins, which through kappa (κ)-opioid 
receptors (KOR), can exert negative feedback on dopamine 
release in the mesolimbic system and glutamate release in the 
NAc (27). This can lead to the mesolimbic system becoming 
hypodopaminergic and down-regulated, giving rise to anhedonia 
and tolerance to the euphoric effects of opioids (29).
The anti-reward system is also mediated by the release of 
CRF from the hypothalamus, which subsequently leads to the 
secretion of cortisol by the adrenal glands (27, 30). In the anti-
reward system, the production of CRF is initially controlled 
by negative feedback at the level of the hypothalamus and 
pituitary; however, this brake may eventually be overcome by 
the production of extra-hypothalamic CRF from the amygdala, 
driven in a feed-forward manner by the secretion of cortisol. 
This drives the noradrenergic stress response (at the level of 
the brainstem) independently of the hypothalamic-pituitary-
adrenal (HPA) axis. The release of dynorphins may also be 
under the control of CRF and conversely CRF release and/or 
function itself may be controlled by dynorphin-KOR signaling 
(31–33). A potential link between dynorphins and stress is also 
supported by the observation that KOR agonists have also been 
shown to increase cortisol levels in humans and monkeys (34, 
35). Ultimately, this dominance of the anti-reward pathway may 
explain the negative emotions, such as malaise and dysphoria, 
experienced during withdrawal [reviewed in (14, 24)].
In OUD, the importance of the anti-reward system during 
the withdrawal state is supported by the evidence that cortisol 
levels are suppressed in patients with active opioid use (36–
38), and then elevated in response to opioid withdrawal upon 
cessation (39–42). HPA axis dysregulation may persist well 
beyond the initial acute withdrawal phase, with one study 
demonstrating that salivary cortisol levels were significantly 
higher in OUD patients compared with controls for at least 25 
days after detoxification (42). Furthermore, heroin craving has 
been shown to be positively correlated with serum cortisol levels 
[and negatively correlated with plasma β-endorphin levels (43)], 
emphasizing the need to target the anti-reward system in the 
long-term management of OUD. Exposure to drug-related cues 
mediates the symptoms of craving in OUD (44–49) and may be 
linked with increased cortisol responses (50), consistent with 
the neuroendocrine underpinnings of craving as described in 
Figure 2. Cue-induced drug seeking is also underpinned by the 
processes of conditioned reinforcement [described by Koob and 
Volkow (51) as a previously neutral stimulus that can reinforce 
behaviors through its association with a primary reinforcer 
and thus become a reinforcer in its own right] and incentive 
salience (defined as motivation for rewards that are derived from 
both a physiological state and previously learned associations 
about a reward cue). In this setting, activation of the dopamine 
system in response to repeated exposure to a reward leads to 
neuroadaptation, ultimately resulting in phasic dopamine system 
activation in response to neutral cues related to the reward, but 
not to the reward itself (22, 51).
Opioid agonist therapies (OAT), such as buprenorphine and 
methadone, have been shown to normalize the HPA axis (52, 
53). However, despite the impact of OAT on the HPA axis, many 
heroin-dependent patients continue to experience negative affect, 
potentially as a result of signaling via extra-hypothalamic CRF (53). 
The significance of CRF in drug addiction has been extensively 
studied in animal models (27). Administration of a CRF receptor 
antagonist has been found to decrease opioid withdrawal-
induced negative emotional states (54) and attenuated heroin self-
administration in animals with extended access to the drug (55). 
Further to these preclinical findings, there has been growing interest 
in the therapeutic potential of selective CRF antagonists in addiction 
disorders and in depression, but to date, clinical trials have been 
unrewarding due to lack of efficacy or due to safety concerns (56). 
However, some preliminary evidence that CRF antagonism may 
reduce craving for heroin, albeit with no significant reduction in 
drug use, has been reported (57). Given the role of the dynorphin-
KOR system in addiction, research efforts have also focused on the 
development of selective KOR antagonists (58, 59).
Over the past decade, functional imaging has provided 
further clarification of the relationship between craving and the 
neurobiological changes of addiction. For example, Li et al. (60) 
assessed neural responses among heroin-dependent patients 
following short-term heroin abstinence using functional brain 
imaging and found that increases in craving in response to drug-
related cues were associated with activation of the mesolimbic 
dopamine pathway and the prefrontal cortex. Furthermore, 
similar functional imaging studies demonstrate involvement of the 
hippocampus and amygdala in cue-elicited craving (24), suggesting 
the importance of memories and emotion as substrates in craving.
CLINICAL ASSESSMENT OF CRAVING  
IN OUD
Assessment of craving through effective patient-physician 
communication is crucial to the clinical management of patients 
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with OUD. Furthermore, the use of simple assessment tools 
can provide further information on craving, which may be 
particularly valuable in the research setting as well as in clinical 
practice. A key challenge in developing reliable tools is the 
subjective nature of craving (61). Broadly, measures of craving 
can be divided into two categories—defined as observational 
and self-reported (61). Observational tools used previously 
in research studies rely on proxy measures, such as choosing 
access to drug over a monetary reward or willingness to work 
to access drug (61). Such tools avoid self-reporting bias and any 
communication challenges patients may face in articulating their 
craving symptoms (61). Such assessments are also less dependent 
on the conscious experience of craving and instead may capture 
unconscious craving impulses (61). However, observational 
methods can be challenging to implement in clinical practice and 
may reflect more than just craving alone (61, 62).
Self-reported craving can be evaluated by tools that are 
specific to craving or as a single item within a broader assessment 
tool (summarized in Table 1) (63, 72). In their simplest form, 
craving assessment tools can be single-item scales, which 
allow the responders to indicate their degree of craving using 
easy-to-understand Likert ratings or visual analogue scales 
(VAS) (61). Alternatively, multi-item scales can be used to 
assess craving (62), for example, the Opioid Craving Scale 
includes three questions each rated on a 0–10 VAS. The first 
question asks “How much do you currently crave opiates?,” 
while the remaining questions relate to cue-induced craving 
and likelihood of use in a prior drug-using environment (63). 
Self-reported assessments can be limited by ceiling and floor 
effects, that is, the scale imposes artificial limitations at either 
extreme, which may prevent distinguishing true differences in 
craving between patients (12). Although multi-item scales may 
offer improved reliability and sensitivity compared with single-
item scales (12, 62), they can be cumbersome, time-consuming, 
and lead to respondent disengagement, demotivation, and 
increased reactivity (62, 63).
In recent years, ecological momentary assessments (EMA) 
have emerged as a novel approach to assessing craving (74, 75). 
EMA involves patient recording of real-time assessments of 
craving using mobile technology at regular, random, or event-
triggered (e.g., when the patient experiences craving) timepoints 
each day (74–77). Thus, EMA has the potential to enhance the 
understanding of craving, particularly in regard to temporal 
fluctuations (74, 75), and potentially to treatment dosing.
The US Food and Drug Administration (FDA) has issued 
guidance on patient-reported outcome instruments, such as self-
reported craving assessments, specifying that instruments should 
meet a variety of criteria, including reliability, validity, specificity, 
and sensitivity (78). Furthermore, additional FDA guidance has 
emphasized that craving tools should complement other end 
points and correlate with a sustained clinical response (79).
CRAVING IN CLINICAL PRACTICE
Some patients receiving maintenance treatment with  buprenorphine 
or methadone continue to use illicit opioids, drop out from OAT 
treatment programs, or experience distressing craving symptoms 
(80). In addition, patients receiving opioid maintenance 
treatments frequently misuse other drugs, including alcohol, 
benzodiazepines, cannabis, and gabapentinoids (81, 82). In 
the European Quality Audit of Opioid Treatment (EQUATOR) 
survey of patients receiving OAT, 60% reported either regular 
or occasional use of illicit drugs while undergoing maintenance 
TABLE 1 | Self-reported craving tools for opioid use disorders.
Tool Number of items Scale Development
Opioid Craving Scale (63) 3 items 0–100 mm VAS for each item (total 
score calculated by averaging the 
scores on the 3 items)
Modified from the Cocaine Craving 
Scale
Heroin Craving Questionnaire 
(61, 64–66)
14- and 45-item versions available 
(45 item version includes five 9-item 
subscales)
7-point Likert scale for each item 
(total score calculated from individual 
items)
Modified from the Cocaine Craving 
Questionnaire
Modified Penn Alcohol Craving Scale 
(67)
5 items 7-point scale (total score calculated 
as mean of 5-item scores)
Modified from the Penn Alcohol Craving 
Scale
Desires for Drug Questionnaire 
(61, 67–69)
13 items within 3 domains (desire and 
intention, negative reinforcement, and 
control)
7-point Likert scale Modified from the Desires for Alcohol 
Questionnaire
Cue-Elicited Craving
Assessment (adapted for
OUD) (46, 70)
1 item, administered after exposure to 
visual cues relating to opioid use
0–10 rating scale OUD-focused version of generic cue 
reactivity test
Stress-Elicited Craving
Assessment (adapted for
OUD) (71)
1 item, administered after exposure to 
stress-inducing imagery
0–100 mm VAS scale OUD-focused version of generic cue 
reactivity test
Screener and Opioid Assessments for 
Pain Patients revised version (72, 73)
24 items (1 item is specific to craving) 0–4 scale (item scores summed for 
total score)
Novel
Obsessive-Compulsive
Drug Use Scale (61, 68, 69)
12 items within 3 domains (thoughts 
and interference, intention to use, and 
control of consumption)
5 choices per item Modified from the Obsessive-
Compulsive Drinking Scale
OUD, Opioid use disorder; VAS, Visual analogue scale.
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treatment, and 27% reported heroin use. Of patients who used 
illicit drugs in addition to OAT, one in six cited lack of control 
of cravings as the reason for illicit drug use (80). Furthermore, 
more serious psychiatric manifestations, such as suicidal ideation, 
depressed mood, and attempts to suppress distressing or intrusive 
thoughts, have been positively correlated with levels of self-
reported opioid craving (83, 84),which is why craving symptoms 
should be monitored upon initiation of OAT.
Identifying and managing triggers for lapse (defined as a 
temporary and controlled return to drug use) and relapse (a 
continuous and without control return to drug use) remains an 
important part of the clinical management of OUD (85). Much 
research has focused on identifying predictors of relapse in 
substance use disorders, and one of the strongest candidates to 
emerge from these studies is craving (86). Although earlier studies 
provided inconsistent conclusions on the extent to which craving 
is associated with relapse (74), this may be due to the difficulty 
in measuring craving retrospectively using traditional recall 
methods (74). More recent studies utilizing EMA techniques 
have provided robust evidence that drug craving correlates 
with risk of subsequent opioid use both in patients receiving 
buprenorphine or methadone maintenance treatment and in 
the post-detoxification setting (74, 87–90). Furthermore, EMA 
methodology has demonstrated that the intensity of craving can 
increase linearly prior to drug use (87), and that the strength 
of opioid craving is positively associated with the severity of 
dependence and negatively associated with readiness to change 
drug use (91). Beyond the simple risk of relapse, the presence of 
drug craving can also be a distressing symptom and be disruptive 
to the functioning of patients (92).
To identify and manage the causes of craving, it may be useful 
to distinguish between background (tonic) and cue-induced 
(phasic) craving. Background craving is a slowly changing overall 
level of craving that occurs in the absence of external cues and 
may reflect the negative affect associated with abstinence or 
drug withdrawal and activation of the anti-reward system (9). 
In support of this theory, a correlation between negative affect 
and craving has been observed for many substance use disorders 
(74), and in OUD patients undergoing opioid withdrawal (93). 
In a study of patients with prescription-opioid dependence who 
had undergone medically-assisted withdrawal up to 14 days 
previously, patients with low levels of positive affect were found 
to be more vulnerable to craving on days when their positive 
affect was even lower than average (75).
In addition to background craving, episodes of fast-onset, 
relatively short duration spikes of craving (phasic craving) can 
be induced by specific drug cues or stressful life events (9), 
for which craving intensity correlates with stress severity (94). 
Of note, drug cue exposure and stress episodes can also have 
additive effects on drug craving (49). Measurements of the 
intensity, duration, and frequency of these craving episodes may 
all provide useful prognostic information regarding the risk of 
relapse (9). Furthermore, the identification of specific triggers for 
craving may also be a valuable therapeutic focus in the clinical 
consultation. EMA may allow greater understanding of both 
the tonic and phasic components of craving, which are typically 
challenging to differentiate outside of laboratory settings (9, 12, 74).
Even among heroin users who have been abstinent for greater 
than a year, drug-related cues still have the potential to elicit 
craving responses (47, 48), highlighting the enduring nature of 
craving among patients with a history of drug dependence. The 
influence of different cues on craving may also be dependent 
on the type of opioid dependence: in heroin dependence, cue-
related craving was stimulated more intensely by paraphernalia 
images (e.g., needles), whereas patients with analgesic 
dependence were more stimulated by pills and pill bottles (46). 
The relationship between life stressors, craving, and relapse is 
complex and likely to be subject to significant inter-individual 
differences. For example, preliminary data suggest that women 
may experience greater increases in craving in response to 
stress than men (95).
Compared with drug cues, the relationship between pain and 
craving is less clear. In patients maintained on OAT, chronic pain 
was associated with three-fold higher odds of experiencing craving 
for opioids, although this did not lead to a significant increase in 
drug use (96). Conversely, in patients using prescription opioids 
for the treatment of chronic pain, craving was not found to be 
associated with pain itself, but rather with co-occurring anxiety 
and depressive symptoms, or with a perception of a magnified 
threat value of pain (97–99). For these patients, the intensity of 
craving is correlated with the risk of opioid misuse (70, 98, 100). 
Many of these patients may require treatment with OAT in order 
to improve outcomes (101).
CRAVING AS A THERAPEUTIC TARGET  
IN OUD
Inhibition of craving has long been a goal of OUD treatment 
(5). As early as the 1960s, experiments were being conducted 
using electric shock-based aversion therapy to suppress 
craving among patients addicted to synthetic opiates (102). 
In modern times, several pharmacological therapies, notably 
buprenorphine and methadone, are now available for the 
treatment of OUD (103). A comparison of the pharmacological 
characteristics and treatment regimens for methadone and 
buprenorphine is presented in Table 2. Methadone is a full 
μ-opioid receptor agonist, whereas buprenorphine is a high-
affinity partial μ-opioid receptor agonist (103). Consequently, 
buprenorphine is associated with a ceiling effect with respect 
to the risk of respiratory depression (103). As a result of this 
high-affinity binding with buprenorphine, the effects from 
any additional illicit opioid use during maintenance treatment 
can be blocked (103). Other treatment options, including 
intravenous diamorphine, oral L-methadone, and slow-release 
oral morphine, have limited availability in most countries and 
are not considered in this review article.
Numerous studies have demonstrated that buprenorphine 
and methadone can reduce craving in OUD patients (108, 109), 
which may explain why relapse rates are higher in patients who 
undergo detoxification or receive psychosocial interventions 
alone (105). Methadone was the first pharmacotherapy approved 
in OUD (7) and a systematic review performed by Fareed et al. 
(108) in 2011 identified seven studies that provided evidence 
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supporting a role for methadone in reducing craving for heroin. 
This included a study by Shi et al. (110), which demonstrated that 
long-term methadone maintenance both improved mood and 
reduced cue-induced craving. A clear illustration of the impact 
of OAT on craving emerged from a randomized controlled trial 
comparing buprenorphine/naloxone formulation with placebo 
over 4 weeks in patients with opiate dependence. In this study, 
where craving was measured on a 0–100 mm VAS, mean craving 
more than halved, with a baseline score of 62.4 reducing to 29.8 
after 4 weeks of treatment with a sublingual tablet formulation 
of 16 mg buprenorphine/4 mg naloxone (p < 0.0001, Figure 4) 
[(111) and unpublished data].
For both buprenorphine and methadone, the impact on 
craving is dose dependent (112, 113), and it is clear that in order 
to adequately suppress craving, buprenorphine and methadone 
must be carefully up-titrated to achieve the optimal dose for 
each patient (7). The relationship between buprenorphine dose 
and craving suppression is believed to be determined by the 
level of availability of μ-opioid receptors (114), and this has 
been explored in OUD patients using self-reported craving 
questionnaires and positron emission tomography with a 
μ-opioid receptor radioligand to explore receptor occupancy. In 
a preliminary study, Zubieta et al. (115) found that increasing 
buprenorphine dose {up to 16 mg given as a sublingual liquid 
[higher bioavailability compared to a sublingual tablet (116)]} 
was associated with a significantly greater suppression of 
craving scores and a 79–95% reduction in μ-opioid receptor 
availability with the 16 mg dose compared with placebo. This 
was corroborated by Greenwald et al. (117) who found that 
higher buprenorphine doses (up to 32 mg given as a tablet*) led 
to increased plasma buprenorphine levels, decreased μ-opioid 
receptor availability, and decreased withdrawal symptoms. In 
the same study, heroin craving was found to be significantly 
correlated with μ-opioid receptor availability and negatively 
correlated with buprenorphine plasma levels. These results 
were expanded in a further study exploring the chronology of 
μ-opioid receptor availability after buprenorphine dosing in 
heroin-dependent volunteers. In this study, craving intensity 
increased significantly from 4 to 76 hours post-dosing, correlating 
with increasing μ-opioid receptor availability from 30% to 
82% over this time period among patients who had received 
buprenorphine (118).
In addition to its ability to reduce symptoms of withdrawal 
and craving in OUD, buprenorphine may also have a 
therapeutic impact on dysphoria (119), potentially leading 
to improvements in treatment retention and quality of life. The 
impact of buprenorphine on mood may relate to the antagonism it 
exhibits at κ-opioid receptors, as there is growing evidence that 
signaling through these receptors plays a role in the dysphoria 
and increased sensitivity to stress associated with the anti-reward 
pathway (120).
Substance use disorders can also be treated with the opioid 
antagonist naltrexone (121). However, in the context of OUD, 
naltrexone treatment may increase negative affect and craving 
through activation of the HPA axis by removal of tonic inhibition 
by endogenous opioids (122). Consistent with this, studies 
TABLE 2 | Comparison of oral/sublingual buprenorphine and methadone in OUD 
maintenance treatment.
Buprenorphine Methadone
Pharmacological targets • Partial μ-opioid 
receptor agonist 
(104)
• δ-opioid receptor 
antagonist (104)
• κ-opioid receptor 
antagonist (104)
• Opioid-like 
receptor-1 agonist 
(104)
• Full μ-opioid receptor 
agonist (105)
• N-methyl-D-aspartate 
receptor antagonist 
(105)
Average half-life • 32 h (106) • 22 h (106)
Duration of induction • ~2–3 days (107) • 2–4 weeks (“start low, 
go slow”) (7)
Typical induction 
regimen
• 2–8 mg on Day 1 (7)
• Each dose 
increased by 
2–4 mg up to 
24 mg daily (7)
• ≤30 mg/day (7)
• Increases of 
5–10 mg over 5 or 
more days (7)
Typical maintenance 
dose
• Maximum 24*mg 
daily (107)
• 60–120 mg daily (7)
Overdose risk • Low risk of 
overdose because 
of partial agonist 
effect and 
ceiling effect 
for respiratory 
depression (7)
• Higher risk from 
overdose, particularly 
during induction (7)
*Higher maximum doses exist for some countries. Please consult local prescribing 
information. OUD, opioid use disorder.
FIGURE 4 | Impact of buprenorphine on self-reported opiate craving 
among OUD patients (111). Patients were randomized to double-
blind treatment with sublingual tablets consisting of buprenorphine 
(16 mg), buprenorphine-naloxone (16 mg/4 mg), or placebo given 
daily for 4 weeks. Self-reported opiate craving was assessed as the 
peak craving during the prior 24 hours measured on a 0–100 mm 
visual analogue scale, with higher scores representing greater craving. 
Statistically significant reductions in craving (p < 0.001) were reported 
for comparisons between buprenorphine and buprenorphine-naloxone 
groups versus placebo at all post-baseline time points. OUD, opioid 
use disorder. Reproduced with permission from the Massachusetts 
Medical Society.
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in OUD have demonstrated poor patient adherence to oral 
naltrexone and failed to show any therapeutic impact of this drug 
on craving (105, 109, 123, 124).
NON-PHARMACOLOGICAL 
INTERVENTIONS
In substance use disorders, patients may benefit from a range of 
non-pharmacological interventions, such as cognitive behavioral 
therapy (CBT), motivational interventions, and contingency 
management (125). Motivational interventions/interviews 
typically involve brief sessions in which a counselor supports the 
patients in becoming motivated to change their drug use behavior 
(125, 126). Contingency management approaches provide direct 
rewards (e.g., vouchers, prizes, or special privileges) to the patients 
in response to a desired behavior (e.g., drug abstinence) (127).
CBT has been shown to be effective as an integral part of 
treatment programs that aim to help prevent relapses (125). 
However, whether CBT has a direct benefit on craving is unclear, 
as results from studies to date have been inconsistent (128, 129). 
In a study by Ling et al. (128), no significant differences in craving 
were observed between patients treated with buprenorphine 
and standard medical management (limited counseling) or 
buprenorphine combined with either CBT (weekly counseling 
sessions, exercises, and homework) or contingency management. 
In contrast, more promising results were obtained from a study 
of patients receiving methadone maintenance therapy and 
combined CBT and contingency management. In this study, 
significantly decreased craving over the course of a 12-week 
period was reported, although it was limited by the lack of a 
control arm (129).
Mindfulness, broadly defined as a “systemic development 
of attention to present moment experience with an attitude 
of acceptance and non-judging” (130) has been linked with 
reduced craving in substance use disorders, albeit current 
evidence has limitations and displays heterogeneity between 
studies (130–133). In a few studies in patients receiving 
opioid treatment for chronic pain, mindfulness has been 
significantly inversely correlated with opioid craving (134–
136). Mindfulness-based relapse prevention (MBRP) is a novel 
approach to relapse prevention (a cognitive behavioral group 
therapy) (137). MBRP has been shown to reduce substance use 
compared with treatment as usual in patients with substance 
use disorders in both outpatient and residential settings 
(137–139). MBRP may prepare patients for environmental 
relapse risks they encounter after completing residential 
treatment programs.
Although the extent to which mindfulness can influence the 
underlying neurobiological changes in addiction is unclear, 
preliminary evidence in both addiction and non-addiction settings 
suggests that mindfulness approaches can influence the HPA 
axis (140–144) and lead to structural changes, including a 
reduction in gray matter density in the amygdala and an 
increase in gray matter concentration within the hippocampus 
(145, 146).
EXPERT OPINION
Craving is a core facet of OUD that has been shown to be associated 
with the risk of aberrant drug use and relapse in numerous 
studies. It is underpinned by neurobiological and neuroendocrine 
adaptations that lead to the dominance of an anti-reward pathway 
and a change in the set-point of hedonic tone. In daily clinical 
practice, craving is often still not adequately assessed; however, 
identifying craving triggers and evaluating the intensity and 
frequency of craving episodes can be an important part of the 
management of patients with OUD. Furthermore, craving should 
be considered as an important treatment target to reduce the risk 
of relapse and to improve patients’ quality of life. When used at 
optimal doses, pharmacological therapies, such as buprenorphine 
and methadone, can significantly reduce craving and reduce the 
risk of relapse. Moreover, evidence to support the benefits of non-
pharmacological treatments, such as mindfulness-based therapies, 
as a supplementary treatment to OAT is beginning to emerge. 
Despite the positive impact of these treatments, some patients 
remain at risk of craving and, as a result, relapse to opioids. Patients 
may also continue to be burdened by the residual negative affect 
and dysphoria that result from the neurobiological adaptations 
associated with addiction. These patients frequently misuse other 
substances, such as central nervous system depressants like alcohol 
and cannabis, in an effort to self-medicate for the negative affect 
associated with the overactive amygdala. It is hoped that future 
studies will further our understanding of the neurobiological basis 
of craving and drive the development of novel therapeutic strategies 
along with optimized use of existing treatments in order to improve 
outcomes for the growing numbers of patients affected by OUD.
*Note: 32 mg dose of buprenorphine is not licensed in all 
countries (see local prescribing information for details).
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